Blood Collection Tubes for Liquid Biopsy Market Growth | 2028

The blood collection tubes for liquid biopsy market is projected to reach US$ 256.26 million by 2028 from US$ 79.03 million in 2021; it is estimated to grow at a CAGR of 18.3% from 2021 to 2028.

Liquid biopsy is a noninvasive alternative to surgical biopsies, which allows doctors to gain significant information about the detected tumors. Cancer DNA traces detected in a blood sample can reveal which treatments are more suitable for a given patient. The possibility of circulating cell-free DNA (cfDNA) analysis through liquid biopsy has enabled the development of numerous specialized measurement techniques. In the last few years, there has been a surge in interest in the (pre-) analytical conditions of the liquid biopsy workflow.

Strategic Insights

The blood collection tubes for liquid biopsy market is segmented on the basis of product, material, application, end user, and geography. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. The report offers in-depth insights into the market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with the analysis of the competitive landscape of leading market players.     

Lucrative Regions for Blood Collection Tubes for Liquid Biopsy Market

Get more information on this report : Request Free Sample PDF

Market Insights

Increase in Prevalence of Cancer Drives Blood Collection Tubes for Liquid Biopsy Market Growth

Health systems across the world are witnessing a substantial increase in the prevalence of cancer. According to the World Health Organization (WHO), cancer is the second-leading cause of mortality worldwide. Moreover, the International Agency for Research on Cancer (IARC) states the global cancer burden reached 19.3 million cases and 9.96 million cancer deaths in 2020. According to the data published by the WHO, in 2019, ~9.6 million deaths were caused by cancer across the world. Further, prostate, lung, colorectal, liver, and stomach cancer are the most observed cancer types in men, while breast, colorectal, and cervical cancer are reported more commonly among women.

According to a study published by the National Cancer Institute, in 2021, the incidence of cancer in the US is likely to reach 1.9 million. In the US, ~0.6 million people were anticipated to die due to cancer in 2021. Moreover, as per data published by Cancer Research UK in 2020, ~0.16 million people in the UK die every year due to cancer. The Globocan report published in 2018 stated that there were 911,014 breast cancer cases and 310,577 deaths due to breast cancer in the world, of which 367,900 and 162,468 breast cancer cases were reported in China and India, respectively.

Liquid biopsies are used for diagnosing non-small cell lung cancer (NSCLC) and screening or as a companion diagnostic for other types of cancers such as colorectal, breast, gastrointestinal, prostate, and ovarian. Early prognosis, reduced cost, therapy monitoring, acquired drug resistance, detection of tumor heterogeneity, and patient comfort are the benefits of liquid biopsy over traditional cancer diagnostics approaches, as it eliminates the need for surgery. As a result, the preference for liquid biopsy is increasing in parallel with the rise in cancer prevalence. Liquid biopsy procedures contribute to an organization's strategy to detect cancer early and precisely, allowing for a quick treatment of cancer patients and enhancing survival rates among them. This factor will ultimately boost the demand for blood collection tubes for collecting samples for performing liquid biopsy procedures in the coming years.

Rise in Demand for Minimally Invasive Diagnostic Tests Contributes Significantly to Blood Collection Tubes for Liquid Biopsy Market Growth

There is a growing preference for minimally invasive or noninvasive tests among patients for diagnostic purposes. Liquid biopsy is possibly performed for early cancer and mutation detection, tumor monitoring throughout treatment, and recurrence monitoring. This technique uses a nonsurgical method in which blood samples are collected for testing. Researchers can trace all epigenetic and genetic changes in solid tumors using blood samples. Patients are at a lesser risk of infection and blood loss during liquid biopsies, and clinicians can readily conduct these tests multiple times. Moreover, patients prefer minimally invasive procedures as the advanced instruments used in such procedures allow for more delicate and complex work to be performed with lower risk, less pain, and minimal scarring. Moreover, it cuts down the cost and time required for diagnosing the conditions.  

Due to technological advancements in feasibility and processing times, liquid biopsy has recently attracted considerable interest as a noninvasive alternative to tissue biopsy in cancer patients . CTCs, cfDNAs, exosomes, and microvesicles can also be detected in a blood sample, which is making blood-based liquid biopsies more popular. A traditional biopsy is a highly invasive procedure, and surgeons avoid putting the patient at risk. Hence, the growing need for safe and noninvasive cancer diagnostic techniques is fueling the blood collection tubes for liquid biopsy market progress.

Product Insights           

Based on product, the global blood collection tubes for liquid biopsy market is segmented into Ccf DNA tubes, CfRNA tubes, CTC Tubes, GDNA tubes, and others. In 2021, the Ccf DNA tubes segment held the largest share of the market. The same segment is expected to register the highest CAGR in the market during 2021–2028. The ccfDNA tube is used to collect, store, and transport venous whole blood, as well as to stabilize DNA for extraction, cell-free DNA (ccfDNA) from plasma and genomic DNA (gDNA) from the nucleated cellular fraction. Clinical laboratories can use the ccfDNA tube to stabilize samples when they can't be processed on the same day of collection.

End User Insights

Based on end user, the blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, R&D centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest market share in 2021. It is further expected to hold a significant market share during the forecast period.

Blood Collection Tubes for Liquid Biopsy Market, by Product – 2021 and 2028

Get more information on this report : Request Free Sample PDF

Product launches, and mergers and acquisitions are highly adopted strategies by the global blood collection tubes for liquid biopsy market players. A few of the recent key market developments are listed below:

In November 2021, PreAnalytiX GmbH launched the QIAsymphony PAXgene Blood ccfDNA Kit (CE-IVD) that fulfills the new EU IVDR requirements. The PAXgene Blood ccfDNA Tube (CE-IVD), along with the kit, has been verified and validated as an integrated workflow solution for standardized and reproducible ccfDNA processing in diagnostic laboratories requiring automated solutions. In February 2021, Biocept, Inc. announced a collaboration with Protean BioDiagnostics Inc. to investigate the ability of Biocept's Target SelectorTM molecular assay to obtain the EGFR status in NSCLC patients.

The demand for blood collection tubes for liquid biopsy decreased upon the onset of the COVID-19 pandemic in 2020. The unprecedented impact of COVID-19 has been far-reaching, and it is claimed to have a more severe impact on cancer patients. The restrictive measures imposed to lower the infection rate have profoundly limited the number of patients undergoing cancer screening, diagnosis, and treatment. Moreover, a surge in pressure due to the growing rate of hospitalization among COVID-19 patients led to the re-profiling of many hospitals and healthcare departments, including oncology clinics, for treating such patients. According to one of the studies, many diagnostic and treatment procedures were canceled or postponed in the world, which included ~2.3 million cancer surgeries.

Blood Collection Tubes for Liquid Biopsy – Market Segmentation

The global blood collection tubes for liquid biopsy market is segmented on the basis of product, material, application, and geography. Based on product, the market has been subsegmented into ccfDNA tubes, cfRNA tubes, CTC tubes, gDNA tubes, intracellular RNA tubes, and others. Based on material, the blood collection tubes for liquid biopsy market is bifurcated into glass and plastic. The blood collection tubes for liquid biopsy market, by application, is further segmented into in-vitro diagnostics (IVD) and research. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.

Company Profiles

• PreAnalytix GmbH
• Biocept,Inc.
• F. HOFFMANN-LA ROCHE LTD
• STRECK
• Norgen Biotek Corp
• Exact Sciences Corporation
• Greiner AG
• MagBio Genomics, Inc.
• Zymo Research Corporation
• Apostle Sciences